{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T01:35:48Z","timestamp":1793928948248,"version":"4.8.0"},"reference-count":76,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.cyto.2025.156971","type":"journal-article","created":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T03:02:36Z","timestamp":1749610956000},"page":"156971","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["FcRn inhibitors in immune thrombocytopenia: A comprehensive review of therapeutic advances and clinical outcomes"],"prefix":"10.1016","volume":"193","author":[{"given":"Mohammad Ali","family":"Nilforoushzadeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazila","family":"Heidari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyedayin","family":"Hosseini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Negar","family":"Ghotbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahdi","family":"Abdollahi Namanloo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirhossein","family":"Heidari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.cyto.2025.156971_bb0005","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.autrev.2017.04.012","article-title":"Pathogenesis of immune thrombocytopenia","volume":"16","author":"Audia","year":"2017","journal-title":"Autoimmun. Rev."},{"issue":"Suppl 5(Suppl 5)","key":"10.1016\/j.cyto.2025.156971_bb0010","doi-asserted-by":"crossref","first-page":"S152","DOI":"10.1016\/j.htct.2023.09.2363","article-title":"Epidemiology of immune thrombocytopenia: study of adult patients at a referral hematology service in northeastern Brazil","volume":"46","author":"Kubrusly","year":"2024","journal-title":"Hematol. Transfus Cell Ther."},{"issue":"5","key":"10.1016\/j.cyto.2025.156971_bb0015","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1080\/17512433.2021.1903315","article-title":"Update on diagnosis and treatment of immune thrombocytopenia","volume":"14","author":"Sandal","year":"2021","journal-title":"Expert. Rev. Clin. Pharmacol."},{"issue":"10","key":"10.1016\/j.cyto.2025.156971_bb0020","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1056\/NEJMcp1810479","article-title":"Immune thrombocytopenia","volume":"381","author":"Cooper","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cyto.2025.156971_bb0025","article-title":"Current therapeutic strategies and perspectives in refractory ITP: what have we learned recently?","volume":"13","author":"Lv","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cyto.2025.156971_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2021.100822","article-title":"Immune thrombocytopenia: a review of upfront treatment strategies","volume":"49","author":"Kochhar","year":"2021","journal-title":"Blood Rev."},{"issue":"12","key":"10.1016\/j.cyto.2025.156971_bb0035","doi-asserted-by":"crossref","first-page":"667","DOI":"10.3390\/medicina56120667","article-title":"Immune thrombocytopenia (ITP): current limitations in patient management","volume":"56","author":"Terrell","year":"2020","journal-title":"Medicina (Kaunas)"},{"issue":"7","key":"10.1016\/j.cyto.2025.156971_bb0040","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1182\/blood.2019003599","article-title":"Identifying and treating refractory ITP: difficulty in diagnosis and role of combination treatment","volume":"135","author":"Miltiadous","year":"2020","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.cyto.2025.156971_bb0045","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1182\/bloodadvances.2019000812","article-title":"Updated international consensus report on the investigation and management of primary immune thrombocytopenia","volume":"3","author":"Provan","year":"2019","journal-title":"Blood Adv."},{"issue":"6","key":"10.1016\/j.cyto.2025.156971_bb0050","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/MOH.0000000000000612","article-title":"An update on the pathophysiology of immune thrombocytopenia","volume":"27","author":"Semple","year":"2020","journal-title":"Curr. Opin. Hematol."},{"issue":"414","key":"10.1016\/j.cyto.2025.156971_bb0055","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan1208","article-title":"The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: a randomized phase 1 study","volume":"9","author":"Kiessling","year":"2017","journal-title":"Sci. Transl. Med."},{"issue":"8","key":"10.1016\/j.cyto.2025.156971_bb0060","first-page":"1229","article-title":"Treatment of ITP","volume":"62","author":"Yokoyama","year":"2021","journal-title":"Rinsho Ketsueki"},{"issue":"2","key":"10.1016\/j.cyto.2025.156971_bb0065","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/j.1749-6632.1965.tb18984.x","article-title":"Similarities between known antiplatelet antibodies and the factor responsible for thrombocytopenia in idiopathic purpura. Physiologic, serologic and isotopic studies","volume":"124","author":"Shulman","year":"1965","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"9","key":"10.1016\/j.cyto.2025.156971_bb0070","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/nm921","article-title":"T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura","volume":"9","author":"Olsson","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.cyto.2025.156971_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.111827","article-title":"The role of BAFF and BAFF-R inhibitors in the treatment of immune thrombocytopenia; a focused review","volume":"131","author":"Nilforoushzadeh","year":"2024","journal-title":"Int. Immunopharmacol."},{"issue":"6","key":"10.1016\/j.cyto.2025.156971_bb0080","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.autrev.2016.02.006","article-title":"Targeting FcgammaRs to treat antibody-dependent autoimmunity","volume":"15","author":"Yu","year":"2016","journal-title":"Autoimmun. Rev."},{"issue":"4","key":"10.1016\/j.cyto.2025.156971_bb0085","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.molimm.2004.07.034","article-title":"Activation of NK cell cytotoxicity","volume":"42","author":"Smyth","year":"2005","journal-title":"Mol. Immunol."},{"issue":"2","key":"10.1016\/j.cyto.2025.156971_bb0090","doi-asserted-by":"crossref","DOI":"10.3390\/jcm6020016","article-title":"Pathogenesis and therapeutic mechanisms in immune thrombocytopenia (ITP)","volume":"6","author":"Zufferey","year":"2017","journal-title":"J. Clin. Med."},{"issue":"2","key":"10.1016\/j.cyto.2025.156971_bb0095","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.tmrv.2007.12.001","article-title":"The mechanisms of action of intravenous immunoglobulin and polyclonal anti-D immunoglobulin in the amelioration of immune thrombocytopenic Purpura: what do we really know?","volume":"22","author":"Crow","year":"2008","journal-title":"Transfus. Med. Rev."},{"key":"10.1016\/j.cyto.2025.156971_bb0100","series-title":"Reference Module in Biomedical Research","first-page":"1","article-title":"Fc receptors in immune responses","author":"Mancardi","year":"2014"},{"issue":"8","key":"10.1016\/j.cyto.2025.156971_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2022.102189","article-title":"Phosphorylation on Syk Y342 is important for both ITAM and hemITAM signaling in platelets","volume":"298","author":"Kostyak","year":"2022","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.cyto.2025.156971_bb0110","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/ni.1706","article-title":"Cross-regulation of signaling by ITAM-associated receptors","volume":"10","author":"Ivashkiv","year":"2009","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.cyto.2025.156971_bb0115","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.668131","article-title":"Targeting Bruton\u2019s tyrosine kinase in inflammatory and autoimmune pathologies","volume":"9","author":"Neys","year":"2021","journal-title":"Front Cell Dev. Biol."},{"issue":"2","key":"10.1016\/j.cyto.2025.156971_bb0120","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1002\/eji.200737741","article-title":"Syk kinase is required for collaborative cytokine production induced through Dectin-1 and toll-like receptors","volume":"38","author":"Dennehy","year":"2008","journal-title":"Eur. J. Immunol."},{"issue":"3","key":"10.1016\/j.cyto.2025.156971_bb0125","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jaci.2020.07.016","article-title":"Targeting FcRn for immunomodulation: benefits, risks, and practical considerations","volume":"146","author":"Peter","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.cyto.2025.156971_bb0130","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.892534","article-title":"Clinical significance of serum albumin and implications of FcRn inhibitor treatment in IgG-mediated autoimmune disorders","volume":"13","author":"Ward","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.cyto.2025.156971_bb0135","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13045-023-01401-z","article-title":"How we treat primary immune thrombocytopenia in adults","volume":"16","author":"Liu","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.cyto.2025.156971_bb0140","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1053\/j.seminhematol.2008.12.005","article-title":"Pathobiology of secondary immune thrombocytopenia","volume":"46","author":"Cines","year":"2009","journal-title":"Semin. Hematol."},{"issue":"1","key":"10.1016\/j.cyto.2025.156971_bb0145","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1182\/asheducation.V2012.1.306.3798320","article-title":"Pathogenesis in immune thrombocytopenia: new insights","volume":"2012","author":"Johnsen","year":"2012","journal-title":"Hematology"},{"issue":"1","key":"10.1016\/j.cyto.2025.156971_bb0150","doi-asserted-by":"crossref","first-page":"7737","DOI":"10.1038\/ncomms8737","article-title":"Desialylation is a mechanism of fc-independent platelet clearance and a therapeutic target in immune thrombocytopenia","volume":"6","author":"Li","year":"2015","journal-title":"Nat. Commun."},{"issue":"8","key":"10.1016\/j.cyto.2025.156971_bb0155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0160563","article-title":"Platelet apoptosis in adult immune thrombocytopenia: insights into the mechanism of damage triggered by auto-antibodies","volume":"11","author":"Goette","year":"2016","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.cyto.2025.156971_bb0160","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/ajh.25680","article-title":"Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia","volume":"95","author":"Newland","year":"2020","journal-title":"Am. J. Hematol."},{"issue":"9","key":"10.1016\/j.cyto.2025.156971_bb0165","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1080\/10245332.2016.1180097","article-title":"Platelet function in adult ITP patients can be either increased or decreased, compared to healthy controls, and is associated with bleeding risk","volume":"21","author":"Middelburg","year":"2016","journal-title":"Hematology"},{"issue":"2","key":"10.1016\/j.cyto.2025.156971_bb0170","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1600-0609.2011.01718.x","article-title":"Autoantibody-mediated complement activation on platelets is a common finding in patients with immune thrombocytopenic purpura (ITP)","volume":"88","author":"Najaoui","year":"2012","journal-title":"Eur. J. Haematol."},{"issue":"11","key":"10.1016\/j.cyto.2025.156971_bb0175","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s00277-008-0535-3","article-title":"Profile of Th17 cytokines (IL-17, TGF-beta, IL-6) and Th1 cytokine (IFN-gamma) in patients with immune thrombocytopenic purpura","volume":"87","author":"Ma","year":"2008","journal-title":"Ann. Hematol."},{"issue":"11","key":"10.1016\/j.cyto.2025.156971_bb0180","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.3324\/haematol.2009.007708","article-title":"High-dose dexamethasone regulates interleukin-18 and interleukin-18 binding protein in idiopathic thrombocytopenic purpura","volume":"94","author":"Shan","year":"2009","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.cyto.2025.156971_bb0185","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.clim.2011.05.003","article-title":"Elevated plasma IL-22 levels correlated with Th1 and Th22 cells in patients with immune thrombocytopenia","volume":"141","author":"Cao","year":"2011","journal-title":"Clin. Immunol."},{"issue":"7","key":"10.1016\/j.cyto.2025.156971_bb0190","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.exphem.2006.03.009","article-title":"Dendritic cells of immune thrombocytopenic purpura (ITP) show increased capacity to present apoptotic platelets to T lymphocytes","volume":"34","author":"Catani","year":"2006","journal-title":"Exp. Hematol."},{"issue":"1","key":"10.1016\/j.cyto.2025.156971_bb0195","doi-asserted-by":"crossref","DOI":"10.1155\/mi\/5578929","article-title":"Efficacy and safety of Syk and BTK inhibitors in immune thrombocytopenia: a comprehensive review of emerging evidence","volume":"2025","author":"Heidari","year":"2025","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.cyto.2025.156971_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106341","article-title":"Profile of IL-36 cytokines (IL-36\u03b1, IL-36\u03b2, IL-36\u03b3 and IL-36Ra) in patients with primary immune thrombocytopenia","volume":"82","author":"Wang","year":"2020","journal-title":"Int. Immunopharmacol."},{"issue":"16","key":"10.1016\/j.cyto.2025.156971_bb0205","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26164907","article-title":"Recent advances in BTK inhibitors for the treatment of inflammatory and autoimmune diseases","volume":"26","author":"Zhang","year":"2021","journal-title":"Molecules"},{"issue":"7","key":"10.1016\/j.cyto.2025.156971_bb0210","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.186.7.1027","article-title":"A critical role for Syk in signal transduction and phagocytosis mediated by Fcgamma receptors on macrophages","volume":"186","author":"Crowley","year":"1997","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.cyto.2025.156971_bb0215","doi-asserted-by":"crossref","first-page":"8408","DOI":"10.1182\/blood-2022-158236","article-title":"Efficacy and safety of tyrosine kinase inhibitors in the treatment of relapsed\/refractory immune thrombocytopenia","volume":"140","author":"Ali","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.cyto.2025.156971_bb0220","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/nri2206","article-title":"Fcgamma receptors as regulators of immune responses","volume":"8","author":"Nimmerjahn","year":"2008","journal-title":"Nat. Rev. Immunol."},{"issue":"8","key":"10.1016\/j.cyto.2025.156971_bb0225","first-page":"2939","article-title":"Helicobacter pylori eradication shifts monocyte Fcgamma receptor balance toward inhibitory FcgammaRIIB in immune thrombocytopenic purpura patients","volume":"118","author":"Asahi","year":"2008","journal-title":"J. Clin. Invest."},{"issue":"3","key":"10.1016\/j.cyto.2025.156971_bb0230","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1080\/10245332.2017.1377902","article-title":"FC gamma receptor polymorphisms in patients with immune thrombocytopenia","volume":"23","author":"Pavkovic","year":"2018","journal-title":"Hematology"},{"issue":"5","key":"10.1016\/j.cyto.2025.156971_bb0235","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/MPH.0b013e3182580908","article-title":"Fcgamma receptor gene polymorphisms in childhood immune thrombocytopenic purpura","volume":"34","author":"Amorim","year":"2012","journal-title":"J. Pediatr. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.cyto.2025.156971_bb0240","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1046\/j.1365-2141.2003.04033.x","article-title":"Fcgamma receptor IIa and IIIa polymorphisms in childhood immune thrombocytopenic purpura","volume":"120","author":"Carcao","year":"2003","journal-title":"Br. J. Haematol."},{"issue":"11","key":"10.1016\/j.cyto.2025.156971_bb0245","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1182\/blood-2013-05-501858","article-title":"Fc\u03b3 receptor IIB gene polymorphism in adult Japanese patients with primary immune thrombocytopenia","volume":"122","author":"Satoh","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.cyto.2025.156971_bb0250","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2300155","article-title":"Interactions of the anti-FcRn monoclonal antibody, rozanolixizumab, with Fcgamma receptors and functional impact on immune cells in vitro","volume":"16","author":"Qureshi","year":"2024","journal-title":"MAbs"},{"issue":"7","key":"10.1016\/j.cyto.2025.156971_bb0255","first-page":"1111","article-title":"Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration","volume":"10","author":"Smith","year":"2018","journal-title":"MAbs"},{"issue":"8","key":"10.1016\/j.cyto.2025.156971_bb0260","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s40261-024-01380-0","article-title":"Pharmacokinetics and pharmacodynamics of Nipocalimab, a neonatal fc receptor blocker, in healthy japanese volunteers","volume":"44","author":"Matsushima","year":"2024","journal-title":"Clin. Drug Investig."},{"issue":"3","key":"10.1016\/j.cyto.2025.156971_bb0265","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jaci.2020.07.015","article-title":"Neonatal fc receptor in human immunity: function and role in therapeutic intervention","volume":"146","author":"Patel","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"issue":"10413","key":"10.1016\/j.cyto.2025.156971_bb0270","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1016\/S0140-6736(23)01460-5","article-title":"Efficacy and safety of the neonatal fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"402","author":"Broome","year":"2023","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.cyto.2025.156971_bb0275","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41577-022-00821-1","article-title":"The therapeutic age of the neonatal fc receptor","volume":"23","author":"Pyzik","year":"2023","journal-title":"Nat. Rev. Immunol."},{"issue":"9","key":"10.1016\/j.cyto.2025.156971_bb0280","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/nri2155","article-title":"FcRn: the neonatal fc receptor comes of age","volume":"7","author":"Roopenian","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.cyto.2025.156971_bb0285","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.3389\/fimmu.2019.01540","article-title":"The neonatal fc receptor (FcRn): a misnomer?","volume":"10","author":"Pyzik","year":"2019","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.cyto.2025.156971_bb0290","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aax9586","article-title":"Blocking FcRn in humans reduces circulating IgG levels and inhibits IgG immune complex-mediated immune responses","volume":"5","author":"Blumberg","year":"2019","journal-title":"Sci. Adv."},{"issue":"5","key":"10.1016\/j.cyto.2025.156971_bb0295","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S1474-4422(23)00077-7","article-title":"Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study","volume":"22","author":"Bril","year":"2023","journal-title":"Lancet Neurol."},{"issue":"7","key":"10.1016\/j.cyto.2025.156971_bb0300","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.cyto.2025.156971_bb0305","series-title":"Stabilization of keratinocyte monolayer integrity in the presence of anti-Desmoglein-3 antibodies through FcRn blockade with Efgartigimod: novel treatment paradigm for pemphigus? Cells","volume":"11","author":"Zakrzewicz","year":"2022"},{"key":"10.1016\/j.cyto.2025.156971_bb0310","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.863095","article-title":"FcRn antagonism leads to a decrease of Desmoglein-specific B cells: secondary analysis of a phase 2 study of Efgartigimod in pemphigus vulgaris and pemphigus Foliaceus","volume":"13","author":"Maho-Vaillant","year":"2022","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.cyto.2025.156971_bb0315","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1172\/JCI97911","article-title":"Neonatal fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans","volume":"128","author":"Ulrichts","year":"2018","journal-title":"J. Clin. Invest."},{"issue":"8","key":"10.1016\/j.cyto.2025.156971_bb0320","first-page":"1637","article-title":"FcRn inhibitors: a novel option for the treatment of myasthenia gravis","volume":"18","author":"Zhu","year":"2023","journal-title":"Neural Regen. Res."},{"key":"10.1016\/j.cyto.2025.156971_bb0325","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2024.1302714","article-title":"Pharmacokinetics and pharmacodynamics across infusion rates of intravenously administered nipocalimab: results of a phase 1, placebo-controlled study","volume":"18","author":"Leu","year":"2024","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.cyto.2025.156971_bb0330","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/j.htct.2022.09.022","article-title":"Selective targeting of Fcrn and igg clearance by Nipocalimab preserves key immune functions","volume":"44","author":"Ling","year":"2022","journal-title":"Hematol, Transfusion Cell Therapy"},{"issue":"2","key":"10.1016\/j.cyto.2025.156971_bb0335","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000207937","article-title":"Safety and efficacy of Nipocalimab in patients with generalized myasthenia gravis: results from the randomized phase 2 vivacity-MG study","volume":"102","author":"Antozzi","year":"2024","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.cyto.2025.156971_bb0340","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-004278","article-title":"Nipocalimab, an anti-FcRn monoclonal antibody, in participants with moderate to severe active rheumatoid arthritis and inadequate response or intolerance to anti-TNF therapy: results from the phase 2a IRIS-RA study","volume":"10","author":"Taylor","year":"2024","journal-title":"RMD Open"},{"issue":"1","key":"10.1016\/j.cyto.2025.156971_bb0345","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/acn3.51946","article-title":"Subcutaneous batoclimab in generalized myasthenia gravis: results from a phase 2a trial with an open-label extension","volume":"11","author":"Nowak","year":"2024","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"4","key":"10.1016\/j.cyto.2025.156971_bb0350","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1001\/jamaneurol.2024.0044","article-title":"Batoclimab vs placebo for generalized myasthenia gravis: a randomized clinical trial","volume":"81","author":"Yan","year":"2024","journal-title":"JAMA Neurol."},{"issue":"1","key":"10.1016\/j.cyto.2025.156971_bb0355","doi-asserted-by":"crossref","DOI":"10.1080\/1547691X.2025.2459934","article-title":"Effects of efgartigimod treatment on humoral and cellular immune responses: analysis of T-cell-dependent antibody response in cynomolgus monkeys","volume":"22","author":"Binazon","year":"2025","journal-title":"J. Immunotoxicol."},{"issue":"1","key":"10.1016\/j.cyto.2025.156971_bb0360","doi-asserted-by":"crossref","DOI":"10.4084\/MJHID.2023.021","article-title":"Sequential use of Efgartigimod and Romiplostim restored platelet response in two multi-refractory thrombocytopenic patients, previously treated with Thrombopoietin receptor agonists","volume":"15","author":"Carpenedo","year":"2023","journal-title":"Mediterr. J. Hematol. Infect Dis."},{"issue":"3","key":"10.1016\/j.cyto.2025.156971_bb0365","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s40259-025-00708-2","article-title":"Targeting the neonatal fc receptor in autoimmune diseases: pipeline and Progress","volume":"39","author":"Gj\u00f8lberg","year":"2025","journal-title":"BioDrugs"},{"issue":"1","key":"10.1016\/j.cyto.2025.156971_bb0370","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2300155","article-title":"Interactions of the anti-FcRn monoclonal antibody, rozanolixizumab, with Fc\u03b3 receptors and functional impact on immune cells in vitro","volume":"16","author":"Qureshi","year":"2024","journal-title":"MAbs"},{"issue":"17","key":"10.1016\/j.cyto.2025.156971_bb0375","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1182\/bloodadvances.2020002003","article-title":"Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia","volume":"4","author":"Robak","year":"2020","journal-title":"Blood Adv."},{"issue":"2","key":"10.1016\/j.cyto.2025.156971_bb0380","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/bjh.19858","article-title":"Inhibition of FcRn with rozanolixizumab in adults with immune thrombocytopenia: two randomised, double-blind, placebo-controlled phase 3 studies and their open-label extension","volume":"206","author":"Cooper","year":"2025","journal-title":"Br. J. Haematol."}],"container-title":["Cytokine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466625001188?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466625001188?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T17:50:27Z","timestamp":1752601827000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043466625001188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":76,"alternative-id":["S1043466625001188"],"URL":"https:\/\/doi.org\/10.1016\/j.cyto.2025.156971","relation":{},"ISSN":["1043-4666"],"issn-type":[{"value":"1043-4666","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"FcRn inhibitors in immune thrombocytopenia: A comprehensive review of therapeutic advances and clinical outcomes","name":"articletitle","label":"Article Title"},{"value":"Cytokine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cyto.2025.156971","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"156971"}}